Dec 2019 Completed Phase I clinical research of KLT-1101

Oct 2018 KLT-1101 won First Prize of "Maker China" Innovation and Entrepreneurship Competition 

Jun 2018 Officially started Phase I clinical research work 

Apr 2018 KLT Pharmaceutical North America Incubator and Business Development Center established 

Feb 2018 Approved by the Clinical Research Ethics Committee 

Oct 2017 Obtained clinical trial permission for the category 1 of therapeutic biological drug from the China Food and Drug Administration

May 2017 Obtained the national science and technology major project for new drug development 

Apr 2017 Passed on-site inspection 

Mar 2017 Completed preclinical study and applied for clinical application 

Sep 2016 Determined KLT-1101 pilot process 

Sep 2016 Completed the comprehensive debugging of GMP standard laboratory 

Dec 2015 Signed to enter the Blue Biomedical Industrial Park in Qingdao High-tech Zone

May 2014 Established the three-level cell bank of KLT-1101 project

Aug 2011 Established KANG LI TAI Pharmaceutical Co., Ltd.